A5085581373- Cancer Immunotherapy and Biomarkers
- Immunotherapy and Immune Responses
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Treatments and Mutations
- T-cell and B-cell Immunology
- Cardiac pacing and defibrillation studies
- Chemical Reactions and Isotopes
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Mechanical Circulatory Support Devices
- Synthesis and biological activity
- Cardiac Structural Anomalies and Repair
Bristol-Myers Squibb (Belgium)
2023
Bristol-Myers Squibb (United States)
2022-2023
In cancer immunotherapy, the blockade of interaction between programmed death-1 and its ligand (PD-1:PD-L1) has proven to be one most promising strategies. However, as mechanisms resistance PD-1/PD-L1 inhibition include variability in tumor cell PD-L1 expression addition standard biopsy immunohistochemistry (IHC), a comprehensive quantitative approach for measuring is required. Herein, we report development characterization an
<title>Abstract</title> <bold>Purpose:</bold>In cancer immunotherapy, the blockade of interaction between programmed death-1 and its ligand (PD-1:PD-L1) has proven to be one most promising strategies. However, as mechanisms resistance PD-1/PD-L1 inhibition include variability in tumor cell PD-L1 expression addition standard biopsy immunohistochemistry (IHC), a comprehensive quantitative approach for measuring is required. Herein, we report development characterization...
<b>Introduction:</b><sup>18</sup>F-BMS-986327 is a PET tracer in development for use target engagement and dose-receptor occupancy studies of LPA<sub>1</sub> antagonists, such as BMS-986278, which being evaluated Phase 2 study lung fibrosis (NCT04308681). Here, the initial results phase 1 <sup>18</sup>F-BMS-986327 are presented. <b>Aims & Objectives:</b> Evaluate safety, tolerability, radiation dosimetry, test/retest repeatability (TRT) <sup>18</sup>F-BMS-986327....